Alector (0Z2) Stock Overview
A late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
0Z2 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Alector, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.23 |
| 52 Week High | US$2.86 |
| 52 Week Low | US$0.81 |
| Beta | 0.67 |
| 1 Month Change | 6.96% |
| 3 Month Change | -53.41% |
| 1 Year Change | -29.31% |
| 3 Year Change | -86.00% |
| 5 Year Change | -90.00% |
| Change since IPO | -91.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0Z2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 4.2% | 1.7% | 0.1% |
| 1Y | -29.3% | -30.9% | 13.5% |
Return vs Industry: 0Z2 exceeded the German Biotechs industry which returned -30.9% over the past year.
Return vs Market: 0Z2 underperformed the German Market which returned 13.5% over the past year.
Price Volatility
| 0Z2 volatility | |
|---|---|
| 0Z2 Average Weekly Movement | 18.2% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 0Z2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0Z2's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 156 | Arnon Rosenthal | www.alector.com |
Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company’s products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial.
Alector, Inc. Fundamentals Summary
| 0Z2 fundamental statistics | |
|---|---|
| Market cap | €134.42m |
| Earnings (TTM) | -€91.50m |
| Revenue (TTM) | €58.64m |
Is 0Z2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0Z2 income statement (TTM) | |
|---|---|
| Revenue | US$69.05m |
| Cost of Revenue | US$185.94m |
| Gross Profit | -US$116.89m |
| Other Expenses | -US$9.16m |
| Earnings | -US$107.74m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | -169.29% |
| Net Profit Margin | -156.03% |
| Debt/Equity Ratio | 16.7% |
How did 0Z2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/28 22:05 |
| End of Day Share Price | 2025/12/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alector, Inc. is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Thomas Shrader | BTIG |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |